CN110157711B - 一种人的srebp1基因编码区全长分段克隆的方法 - Google Patents
一种人的srebp1基因编码区全长分段克隆的方法 Download PDFInfo
- Publication number
- CN110157711B CN110157711B CN201910104768.6A CN201910104768A CN110157711B CN 110157711 B CN110157711 B CN 110157711B CN 201910104768 A CN201910104768 A CN 201910104768A CN 110157711 B CN110157711 B CN 110157711B
- Authority
- CN
- China
- Prior art keywords
- fragment
- pcr
- srebp1
- carrying
- cloning
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108091026890 Coding region Proteins 0.000 title claims abstract description 39
- 238000000034 method Methods 0.000 title claims abstract description 28
- 238000010367 cloning Methods 0.000 title claims abstract description 26
- 101000629597 Homo sapiens Sterol regulatory element-binding protein 1 Proteins 0.000 title claims abstract description 11
- 239000012634 fragment Substances 0.000 claims abstract description 81
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 31
- 238000001976 enzyme digestion Methods 0.000 claims abstract description 29
- 238000012408 PCR amplification Methods 0.000 claims abstract description 23
- 230000003321 amplification Effects 0.000 claims abstract description 17
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 17
- 238000000746 purification Methods 0.000 claims abstract description 15
- 239000013612 plasmid Substances 0.000 claims description 29
- 238000006243 chemical reaction Methods 0.000 claims description 26
- 238000012163 sequencing technique Methods 0.000 claims description 21
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 17
- 238000001514 detection method Methods 0.000 claims description 16
- 238000001962 electrophoresis Methods 0.000 claims description 15
- 230000029087 digestion Effects 0.000 claims description 14
- 108020004414 DNA Proteins 0.000 claims description 13
- 108090000790 Enzymes Proteins 0.000 claims description 13
- 102000004190 Enzymes Human genes 0.000 claims description 12
- 108091008146 restriction endonucleases Proteins 0.000 claims description 11
- 239000013598 vector Substances 0.000 claims description 11
- 238000005520 cutting process Methods 0.000 claims description 10
- 239000000499 gel Substances 0.000 claims description 10
- 239000000872 buffer Substances 0.000 claims description 9
- 239000002299 complementary DNA Substances 0.000 claims description 9
- 238000000246 agarose gel electrophoresis Methods 0.000 claims description 8
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 8
- 229960000723 ampicillin Drugs 0.000 claims description 8
- 230000035939 shock Effects 0.000 claims description 8
- 239000007787 solid Substances 0.000 claims description 8
- 238000003776 cleavage reaction Methods 0.000 claims description 7
- 238000010839 reverse transcription Methods 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 6
- 230000007017 scission Effects 0.000 claims description 6
- 102000006382 Ribonucleases Human genes 0.000 claims description 5
- 108010083644 Ribonucleases Proteins 0.000 claims description 5
- 239000011543 agarose gel Substances 0.000 claims description 5
- 102000012410 DNA Ligases Human genes 0.000 claims description 4
- 108010061982 DNA Ligases Proteins 0.000 claims description 4
- 239000011248 coating agent Substances 0.000 claims description 4
- 238000000576 coating method Methods 0.000 claims description 4
- 108020004999 messenger RNA Proteins 0.000 claims description 4
- 230000009466 transformation Effects 0.000 claims description 4
- 125000004122 cyclic group Chemical group 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 102000049234 human SREBF1 Human genes 0.000 claims description 3
- 238000012257 pre-denaturation Methods 0.000 claims description 3
- 108091092584 GDNA Proteins 0.000 claims description 2
- 238000003892 spreading Methods 0.000 claims description 2
- 239000003292 glue Substances 0.000 claims 3
- 230000002018 overexpression Effects 0.000 abstract description 3
- 238000012216 screening Methods 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 19
- 239000000047 product Substances 0.000 description 9
- 239000013599 cloning vector Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000002156 mixing Methods 0.000 description 7
- 108010074436 Sterol Regulatory Element Binding Protein 1 Proteins 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 102100039164 Acetyl-CoA carboxylase 1 Human genes 0.000 description 2
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 102000009122 CCAAT-Enhancer-Binding Proteins Human genes 0.000 description 2
- 108010048401 CCAAT-Enhancer-Binding Proteins Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 101100377706 Escherichia phage T5 A2.2 gene Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010039731 Fatty Acid Synthases Proteins 0.000 description 2
- 101000963424 Homo sapiens Acetyl-CoA carboxylase 1 Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 description 2
- 102000008078 Sterol Regulatory Element Binding Protein 1 Human genes 0.000 description 2
- 239000012148 binding buffer Substances 0.000 description 2
- 238000007664 blowing Methods 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000011218 segmentation Effects 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 101710159293 Acyl-CoA desaturase 1 Proteins 0.000 description 1
- 101100460704 Aspergillus sp. (strain MF297-2) notI gene Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 101710186200 CCAAT/enhancer-binding protein Proteins 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 102000011026 Fatty Acid Binding Protein 3 Human genes 0.000 description 1
- 108010062715 Fatty Acid Binding Protein 3 Proteins 0.000 description 1
- 101100226596 Gallus gallus FABP gene Proteins 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108010047290 Multifunctional Enzymes Proteins 0.000 description 1
- 102000006833 Multifunctional Enzymes Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
- 102100028897 Stearoyl-CoA desaturase Human genes 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 102000009822 Sterol Regulatory Element Binding Proteins Human genes 0.000 description 1
- 108010020396 Sterol Regulatory Element Binding Proteins Proteins 0.000 description 1
- 102100026839 Sterol regulatory element-binding protein 1 Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 210000000593 adipose tissue white Anatomy 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000005360 mashing Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明公开了一种人的srebp1基因编码区全长分段克隆的方法,该方法包括以下步骤:A1步骤,srebp1基因CDS区分段扩增PCR引物的设计;A2步骤,srebp1基因片段S1与S2的PCR扩增;A3步骤,S1与S2片段的克隆;A4步骤,T‑S1和T‑S2的双酶切与纯化;A5步骤,E‑S1与ET‑S2的片段的连接;本发明为srebp1基因的过表达、干扰序列筛选等以srebp1基因CDS区基因序列为基础的研究与应用提供一种有效的方法。
Description
技术领域
本发明属于生物技术领域,具体涉及一种人的srebp1基因编码区全长分段克隆的方法。
背景技术
固醇调节元件结合蛋白-1c(Sterol regμlatory element binding protein-1c:SREBP-1c)是SREBPs家族中的一员,在人的肝脏、白色脂肪组织等组织中高表达,具有典型的碱性螺旋-环-螺旋亮氨酸拉链结构域,主要负责激活脂肪酸和甘油三酯的从头合成(Eberle et al.,2004;Muller-Wieland et al.,2012;Shimomura etal.,1997;Wang etal.,1994),研究表明,SREBP-1c调节的脂肪酸与甘油三酯的从头合成,主要是通过与下游靶基因启动子中的SRE(5’-TCACNCCAC-3’)序列的结合,从而调控靶基因的转录(Shimano,2001)。其靶基因包括脂肪酸合酶(FASN)、乙酰辅酶A羧化酶α(ACCα)、硬酯酰辅酶A去饱和酶1(SCD1)、脂肪酸结合蛋白3(FABP3)在内的负责脂肪酸从头合成的关键限速酶基因、脂肪酸转运的关键蛋白基因等酶(Kim and Spiegelman,1996;Liang et al.,2002;Muller-Wieland et al.,2012;Shao and Espenshade,2012;Xiao and Song,2013)。此外,SREBP-1c还能与PPARγ以及CCAAT增强子结合蛋白家族(CCAAT enhancer binding proteins,C/EBPs)共同调控脂肪细胞的分化(Kim et al.,1998)。大量研究发现,srebp-1c异常表达导致的脂代谢紊乱与非酒精性脂肪肝、肥胖、血脂异常、动脉粥样硬化、糖尿病、癌症等诸多疾病具有显著的相关性,甚至是疾病发生的主要诱因(Shimano and Sato,2017;Tao et al.,2019;Varghese et al.,2018;Wang etal.,2018;Zhang et al.,2017)。
人的srebp-1c基因定位于17号染色体上,其CDS区全长3525nt,编码1174个氨基酸残基,G/C含量为65.3%,PCR扩增得到srebp-1c mRNA CDS区全长是对其功能研究的基础,由于其CDS区较长,并且GC含量相对较高,扩增起来具有一定的难度,即使更换多种高保真扩增酶均未成功,然而一些普通酶扩增虽然能够实现扩增,但是连接载体后,经测序发现有碱基的突变,不能使用,因此,使用直接扩增法未能得到有效的srebp1基因序列,很难实现对CDS区全长的一次性扩增。
发明内容
为弥补现有技术的不足,本发明通过降低单次扩增长度以提高扩增成功率,应用分段克隆法得到人的srebp1基因编码区(CDS)序列全长,并构建到克隆载体上,为srebp1基因的过表达、干扰序列筛选等以srebp1基因CDS区序列为基础的研究与应用提供一种有效的方法。
为了实现上述目的,本发明采取如下的技术解决方案:
一种人的srebp1基因CDS区分段克隆的方法,包括以下步骤:
A1步骤,srebp1基因CDS区分段扩增PCR引物的设计;
A2步骤,srebp1基因片段S1与S2的PCR扩增;
A3步骤,S1与S2片段的克隆;
A4步骤,T-S1和T-S2的双酶切与纯化;
A5步骤,E-S1与ET-S2的片段的连接;
所述A1步骤,srebp1基因CDS区分段扩增PCR引物的设计的具体步骤为:
从GenBank中下载人srebp1(Accession NO.NM_004176)mRNA序列,对CDS区序列中限制酶酶切位点分析发现,在CDS区的第2149-2154位为BglII酶切位点,以此酶切位点为分界点,设计分段扩增引物,引物序列如下:
①S1片段引物
S1-F:TAT gcggcc gc CACC ATGGACGAGCCACCCTTCAGC
NotI Kozak
S1-R:CAAGGCCCGTGGGAGACTGGTC
②S2片段引物
S2-F:AAGGAAAAAA gcggccgc AGGGGATGCCGTGTCTGTG
NotI
S2-R:GC tctaga GGGGACACGGGGTCTACCTG
XbaI
进一步的,所述的步骤A2具体为:
A2.1步骤,HepG2细胞总RNA的提取及反转录;
A2.2步骤,S1片段的PCR扩增;
A2.3步骤,S2片段的PCR扩增;
其中:A2.1步骤,HepG2细胞总RNA的提取及反转录;
用TRIZOL方法提取HepG2细胞的总RNA,然后反转成cDNA,反转录的体系与条件为:5×g DNA Eraser Buffer 2μl,gDNA Eraser 1μl,Toral RNA 1μg,补RNase Free dH2O至10μl,轻轻吹打混匀,PCR仪上42℃保温2min,然后向上述反应液中加入PrimeScriptRTEnzyme Mix I 1μl,RT Primer Mix 1μl,5×PrimeScript Buffer 2 4μl,RNase FreedH2O 4μl,共20μl,PCR仪上37℃保温15min,85℃保温5s,待温度降至4℃取出cDNA液-20℃保存备用。
A2.2步骤,S1片段的PCR扩增;
用KOD-Plus-Ver.2试剂盒PCR扩增srebp1基因的S1片段,PCR反应体系为:cDNA(50-100ng/μl)1.2μl,引物S1-F和S1-R各0.6μl,10×PCR Buffer 2μl,25mM MgSO4 1.2μl,2mM dNTPs 2μl,KOD-Plus-(1U/μl)1μl,补充ddH2O至20μl;PCR扩增条件为:95℃预变性3min,33个循环反应(95℃30s,66℃30s,72℃90s),72℃10min,取3μl的反应液琼脂糖凝胶电泳检测,琼脂糖凝胶回收纯化S1片段,-20℃保存备用。
A2.3步骤,S2片段的PCR扩增;
PCR反应条件为95℃预变性3min,33个循环反应(95℃30s,65℃30s,72℃90s),72℃10min,其他操作步骤同A2.2。
进一步的,所述A3步骤,S1与S2片段的克隆包括:
A3.1步骤,S1片段的T-A克隆;
A3.2步骤,S2片段的T-A克隆;
其中,A3.1步骤,S1片段的T-A克隆;
取胶回收的S1片段5μl(100-500ng/μl),加入2×Taq PCR Mix 5μl,72℃反应10min,结束后取2μl加入到连接体系中(19-T Simple Vector 1μl,Solution I 5μl,ddH2O 2μl),16℃连接过夜,热激法转化DH5α感受态细胞,涂布到含有氨苄霉素(100ng/μl)的固体LB平板上,12-16h后挑取单克隆菌落,过夜摇菌,提取质粒后用BglII和NotI双酶酶切质粒,电泳检测,并送测序公司测序进一步鉴定,得到S1片段的T-A克隆载体T-S1。
A3.2步骤,S2片段的T-A克隆;
取胶回收的S2片段5μl,加入2×Taq PCR Mix 5μl,72℃反应10min,结束后取2μl加入到连接体系中(19-T Simple Vector 1μl,Solution I 5μl,ddH2O 2μl),16℃连接过夜,热激法转化DH5α感受态细胞,涂布到含有氨苄霉素(100ng/μl)的固体LB平板上,12-16h后挑取单克隆菌落过夜摇菌,提取质粒后用NotI和XbaI双酶酶切质粒,电泳检测,并送测序公司测序进一步鉴定得到S2片段的T-A克隆载体T-S2。
进一步的,所述A4步骤,T-S1和T-S2的双酶切与纯化包括;
A4.1步骤,T-S1的双酶切与纯化;
A4.2步骤,T-S2的双酶切与纯化;
其中,A4.1步骤,T-S1的双酶切与纯化;具体操作如下:
取10μg T-S1质粒,用BglII和NotI限制酶过夜酶切,胶回收一条约2200bp的DNA片段,即T-S1的双酶切后的目的产物,命名为E-S1,-20℃保存备用。
A4.2步骤,T-S2的双酶切与纯化;具体操作如下:
取10μg T-S2质粒,用BglII和NotI限制酶过夜酶切,胶回收一条包含T载体和S2片段的总长度约4000bp的DNA片段,即T-S2的双酶切后的目的产物,命名为ET-S2,-20℃保存备用。
所述A5步骤,E-S1与ET-S2片段的连接;具体操作步骤如下:
E-S1和ET-S2各取50ng,然后加入T4 DNA Ligase 1μl,10×T4 DNA LigaseBuffer 1μl,补充ddH2O至10μl,16℃过夜连接,热激法转化DH5α感受态细胞,涂布至含有氨苄霉素(100ng/μl)的固体LB平板上,12-16h后挑取单克隆菌落过夜摇菌,提取质粒后用XbaI和NotI限制酶酶切质粒,电泳检测,将酶切鉴定正确的质粒送测序公司测序。鉴定正确后即得含有srebp1基因CDS区全长的T克隆载体(T-srebp1)。
有益效果:为克服现有技术中人的SREBP-1c基因CDS区较长,并且GC含量相对较高,一般情况下很难实现对CDS区全长的一次性扩增的缺陷,本发明通过设计酶切位点,应用分段克隆法得到人的srebp1基因CDS区序列全长,并构建到克隆载体上,为srebp1基因的过表达、干扰序列筛选等以srebp1基因CDS区序列为基础的研究与应用提供一种有效的方法。
附图说明
图1是HepG2细胞总RNA的电泳检测。
图2是PCR扩增技术流程示意图。
图3是S1和S2片段PCR扩增产物电泳检测。
图4是T-S1和T-S2质粒双酶切鉴定。
图5是T-S1和T-S2双酶切胶回收鉴定。
图6是T-srebp1双酶切鉴定。
图7是部分测序图。
图8是部分测序结果与NCBI公布序列的比对图。
具体实施方式
下面结合附图和实施例对本发明进行详细描述,在以下的实施例中,如无特殊说明,采用的材料均为本领域公知的材料。
实施例
A1步骤,srebp1基因CDS区分段扩增PCR引物的设计;
A2步骤,srebp1基因片段S1与S2的PCR扩增;
A3步骤,S1与S2片段的克隆;
A4步骤,T-S1和T-S2的双酶切与纯化;
A5步骤,E-S1与ET-S2的片段的连接。
第一步:srebp1基因CDS区分段扩增PCR引物的设计
从GenBank中下载人srebp1(Accession NO.NM_004176)mRNA序列,对CDS区序列中限制酶酶切位点分析发现,在CDS区的第2149-2154位为BglII酶切位点,以此酶切位点为分界点,设计分段PCR扩增引物,引物序列如下:
①S1片段引物
S1-F:TAT gcggcc gc CACC ATGGACGAGCCACCCTTCAGC
NotI Kozak
S1-R:CAAGGCCCGTGGGAGACTGGTC
②S2片段引物
S2-F:AAGGAAAAAA gcggccgc AGGGGATGCCGTGTCTGTG
NotI
S2-R:GC tctaga GGGGACACGGGGTCTACCTG
XbaI
由于分段法扩增的技术难题在于如何分段及分段数量,因此,本发明首先将srebp1分成两段,然后再连接成一条完整的srebp1序列,在此过程需要借助限制酶,对于限制酶的选择起到关键作用,BglII对srebp1来说是单酶切位点并且在中间或者靠近中间位置,因此选择BglII作为分界点。
第二步:srebp1基因片段S1与S2的PCR扩增
2.1HepG2细胞总RNA的提取及反转录;
用TRIZOL方法提取HepG2细胞的总RNA,具体操作步骤如下:
1)取35mm培养皿中生长状态良好的HepG2细胞,去除培养液,用1×PBS清洗一次;
2)向皿中加入1ml的RNAiso Plus,轻微晃动,使RNAiso Plus均匀分布于细胞表面,室温静置2min,用移液枪反复吹打细胞2min;
3)转移裂解液至离心管中;室温静置5min;
4)加入氯仿200μl,震荡混匀至乳白色;
5)12000×g 4℃离心15min;
6)转移上清液至另一新的离心管中;
7)向上清液中加入等体积的异丙醇,上下颠倒混匀,室温静置10min;
8)12000×g 4℃离心10min,白色沉淀即为RNA;
9)小心弃上清,加入1ml 75%乙醇,上下颠倒数次,7500×g 4℃离心5min,弃去上清,重复此步骤1次;
10)打开离心管盖,室温干燥沉淀几分钟,加入50μl RNase-free ddH2O溶解RNA;
11)取2μl用于琼脂糖凝胶电泳检测,另取2μl用多功能酶标仪测量浓度,剩余冰置备用。
将提取的总RNA反转录成cDNA,具体操作步骤如下:
去除基因组DNA体系如表1.1-1,
表1.1-1去除基因组DNA反应
补RNase Free ddH2O至总体积10μL,轻轻吹打混匀,PCR仪上42℃保温2min,取出后冰上放置,随后在此该体系中加入10μL的反转录体系(表1.1-2);
表1.1-2反转录体系
总体积20μL,PCR仪上37℃保温15min,85℃保温5s,待温度降至4℃取出,将cDNA放置-20℃保存备用。
2.2 S1片段的PCR扩增,具体操作步骤如下;
用KOD-Plus-Ver.2试剂盒PCR扩增srebp1基因的S1片段,PCR反应体系如表2.2-1;
表2.2-1 PCR反应体系
然后将PCR反应体系在PCR仪器上按照特定的反应条件(表2.2-2)进行扩增。
表2.2-2 PCR反应条件
取3μl的PCR反应产物琼脂糖凝胶电泳检测,-20℃保存备用。
2.3S2片段的PCR扩增;
S2片段的PCR扩增反应体系与S1片段的PCR扩增反应体系相同,反应条件见表2.3-1;
取3μl的PCR反应产物琼脂糖凝胶电泳检测,-20℃保存备用。
表2.3-1PCR反应条件
第三步,S1与S2片段的克隆包括:
3.1S1片段的T-A克隆;
胶回收的方法纯化S1片段,操作步骤如下
1)将PCR产物用1%琼脂糖凝胶电泳,约40min,S1条带与杂带分开;
2)紫外灯下,切取含S1条带的琼脂糖并称重,捣碎后放入1.5mL离心管中,按琼脂糖胶质量:Binding Buffer(XP2)=1g:1ml的比例加入适量Binding Buffer(XP2);
3)混匀后,50-60℃水浴,每2-3min左右颠倒混匀一次,直至琼脂糖胶块完全溶化;
4)吸取步骤3中的混合液移至DNA吸附柱,10000×g离心1min;
5)加300μL Binding Buffer(XP2),13000×g离心1min;
6)去除套管内液体,加入700μL SPW Wash Buffer,12000×g离心30s;
7)重复步骤6)一次;
8)吸附柱置于新套管,12000×g离心2min,弃去套管;
9)吸附柱置于新的1.5ml离心管中,加入65℃预热的ddH2O(30-50μL)室温静置2min,12000×g离心1min,1.5ml离心管中透明溶液即为纯化的S1片段。
取纯化的S1片段5μl(100 -500ng/μl),加入2×Taq PCR Mix 5μl,72℃加“A”反应10min,然后进行连接,连接体系见表3.1-1;
表3.1-1连接体系
16℃过夜连接,热激法转化DH5α感受态细胞,然后涂布到含有氨苄霉素(100ng/μl)的固体LB平板上,12-16h后挑取单克隆菌落过夜摇菌,提取质粒,多功能酶标仪测定浓度后,取1μg用BglII和NotI双酶酶切鉴定,酶切反应体系见表3.1-2;
表3.1-2酶切体系
37℃保温2h,电泳检测,将酶切鉴定正确的质粒送测序公司测序。测序结果正确后即得到S1片段的克隆载体,命名为T-S1。
3.2S2片段的T-A克隆;
S2片段的T-A克隆方法与S1片段的T-A克隆方法相同,但在克隆载体鉴定时使用的限制酶是NotI和XbaI。
第四步,T-S1和T-S2的双酶切与纯化;
4.1T-S1的双酶切与纯化;
取T-S1质粒10μg,用BglII和NotI双酶酶切,酶切体系见表4.1-1,
表4.1-1T-S1双酶切反应体系
37℃保温2h,胶回收一条约2200bp的DNA片段,命名为E-S1,-20℃保存备用。
4.2T-S2的双酶切与纯化;
取T-S2质粒10μg,用BglII和NotI双酶酶切,酶切体系见表4.2-1,
表4.2-1T-S2双酶切反应体系
37℃酶切反应2h,胶回收一条约4000bp的DNA片段,命名为ET-S2,-20℃保存备用。
第五步E-S1与ET-S2的连接;
E-S1和ET-S2各取50-100ng,进行连接,连接体系见表5-1;
表5-1E-S1与ET-S2的连接体系
16℃过夜连接,热激法转化DH5α感受态细胞,涂布至含有氨苄霉素(100ng/μl)的固体LB平板上,12-16h后挑取单克隆菌落过夜摇菌,提取质粒后用XbaI和NotI双酶酶切,电泳检测,将酶切鉴定正确的质粒送测序公司测序。测序正确的质粒即含有srebp1基因CDS区全长的T克隆载体,命名为T-srebp1。
第六步 结果验证
6.1HepG2细胞总RNA的提取及反转录;
用TRIZOL方法提取HepG2细胞的总RNA,电泳检测可见明显的3条带,从下至上依次是5.8s,18s,28s(图1)。然后反转成cDNA,-20℃保存备用。
6.2S1和S2片段的PCR扩增;
PCR扩增srebp1基因的S1片段和S2片段,PCR扩增技术流程示意图如图2,PCR产物琼脂糖凝胶电泳检测(图3),图3的1和2孔为S1片段电泳结果,2200bp处为S1片段,下方1000bp处条带为杂带;图3的3和4孔为S2片段电泳结果,1300bp处为S2片段,与预期结果均相符。
6.3S1与S2片段的T-A克隆:
胶回收S1和S2片段,加“A”后分别与19-T Simple Vector连接,构建T-S1和T-S2克隆载体。T-S1用BglII/NotI双酶切鉴定,T-S2用BglII/XbaI双酶切鉴定,双酶切产物电泳结果见图4,图4中1和2号孔为T-S2双酶切产物电泳结果,显示在2692bp与1312bp处分别有一条条带,与预期结果相符;图4中3和4孔为T-S1双酶切产物电泳结果,显示在2692与2164bp分别有一条条带,与预期结果相符。
6.4T-S1和T-S2双酶切检测与纯化
T-S1和T-S2均用BglII和NotI双酶酶切,酶切产物琼脂糖凝胶电泳,结果见图5。图5中1和2孔为T-S2双酶切结果,可见一条约4000bp的条带,与预期相符,并胶回收纯化此条带,即ET-S2。图5中3和4孔为T-S1双酶酶切结果,可见一条约2700bp的条带与一条约2200bp的条带,与预期相符,胶回收纯化2200bp的条带,即E-S1;
6.5E-S1片段与ET-S2片段连接
E-S1和ET-S2连接后转化转化DH5α感受态细胞,经挑菌、摇菌提取质粒,用NotI和XbaI双酶酶切鉴定(图6)见,图6中1号和2号孔均为E-S1和ET-S2连接后的质粒,显示在约3500bp与2700bp分别有一条带,其中3500bp条带包含了srebp1基因CDS区全长,最终T-srebp1构建成功。
实验过程中,每步载体的构建,在提取质粒双酶切鉴定正确后需测序鉴定,以确保得到的srebp1基因CDS区序列与NCBI公布的一致。部分测序结果见图7,部分测序结果与NCBI公布序列的比对结果见图8。
以上所述,仅为本发明创造较佳的具体实施方式,但本发明创造的保护范围并不局限于此,任何熟悉本技术领域的技术人员在本发明创造披露的技术范围内,根据本发明创造的技术方案及其发明构思加以等同替换或改变,都应涵盖在本发明创造的保护范围之内。
Claims (2)
1.一种人的srebp1基因编码区分段克隆的方法,其特征在于,包括以下步骤:
A1步骤,srebp1基因CDS区分段扩增PCR引物的设计;
A2步骤,srebp1基因片段S1与S2的PCR扩增;
A3步骤,S1与S2片段的克隆;
A4步骤,T-S1和T-S2的双酶切与纯化;
A5步骤,E-S1与ET-S2的片段的连接;
其中,A1步骤中,从GenBank中下载人srebp1 mRNA序列,在CDS区的第2149-2154位为BglII酶切位点,以此酶切位点为分界点,设计分段扩增引物,引物序列如下:
①S1片段引物
S1-F:TAT gcggcc gc CACC ATGGACGAGCCACCCTTCAGC
NotI Kozak
S1-R:CAAGGCCCGTGGGAGACTGGTC
②S2片段引物
S2-F:AAGGAAAAAA gcggccgc AGGGGATGCCGTGTCTGTG
NotI
S2-R:GC tctaga GGGGACACGGGGTCTACCTG
XbaI
所述A2步骤包括:
A2.1步骤,HepG2细胞总RNA的提取及反转录:
用TRIZOL方法提取HepG2细胞的总RNA,然后反转成cDNA,反转录的体系与条件为:5×gDNA Eraser Buffer 2μl,gDNA Eraser 1μl,Toral RNA 1μg,补RNase Free dH2O至10μl;PCR仪上42℃保温2min,然后向上述反应液中加入PrimeScriptRT Enzyme Mix I 1μl,RTPrimer Mix 1μl,5×PrimeScript Buffer 24μl,RNase Free dH2O 4μl,共20μl,PCR仪上37℃保温15min,85℃保温5s,待温度降至4℃取出cDNA液-20℃保存备用;
A2.2步骤,S1片段的PCR扩增:
用KOD-Plus-Ver.2试剂盒PCR扩增srebp1基因的S1片段,PCR反应体系为:cDNA 1.2μl,引物S1-F和S1-R各0.6μl,10×PCRBuffer 2μl,25mM MgSO41.2μl,2mM dNTPs 2μl,KOD-Plus-(1U/μl)1μl,补充ddH2O至20μl;PCR扩增条件为:95℃预变性3min,依次以条件95℃30s,66℃30s,72℃90s进行33个循环反应,然后于72℃10min,取3μl的反应液琼脂糖凝胶电泳检测,琼脂糖凝胶回收纯化S1片段,-20℃保存备用;
A2.3步骤,S2片段的PCR扩增:
用KOD-Plus-Ver.2试剂盒PCR扩增srebp1基因的S2片段,PCR反应体系为:cDNA1.2μl,引物S2-F和S2-R各0.6μl,10×PCR Buffer 2μl,25mM MgSO41.2μl,2mM dNTPs 2μl,KOD-Plus-(1U/μl)1μl,补充ddH2O至20μl;PCR扩增条件为:95℃预变性3min,33个循环反应(95℃30s,65℃30s,72℃90s),72℃10min,取3μl的反应液琼脂糖凝胶电泳检测,琼脂糖凝胶回收纯化S2片段,-20℃保存备用;
所述A3步骤包括:
A3.1步骤,S1片段的T-A克隆:
取胶回收的S1片段5μl,加入2×Taq PCR Mix 5μl,72℃反应10min,结束后取2μl加入到连接体系中,16℃连接过夜,热激法转化DH5α感受态细胞,涂布到含有氨苄霉素100ng/μl的固体LB平板上,12-16h后挑取单克隆菌落过夜摇菌,提取质粒后用BglII和NotI双酶酶切质粒,电泳检测,并送测序公司测序进一步鉴定,得到S1片段的T-A克隆载体T-S1;
A3.2步骤,S2片段的T-A克隆:
取胶回收的S2片段5μl,加入2×Taq PCR Mix 5μl,72℃反应10min,结束后取2μl加入到连接体系中,16℃连接过夜,热激法转化DH5α感受态细胞,涂布到含有氨苄霉素100ng/μl的固体LB平板上,12-16h后挑取单克隆菌落过夜摇菌,提取质粒后用NotI和XbaI双酶酶切质粒,电泳检测,并送测序公司测序进一步鉴定得到S2片段的T-A克隆载体T-S2;
所述A4步骤包括:
A4.1步骤,T-S1的双酶切与纯化:取10μg T-S1质粒,用BglII和NotI限制酶过夜酶切,胶回收一条约2200bp的DNA片段,即T-S1的双酶切后的目的产物,命名为E-S1,-20℃保存备用;
A4.2步骤,T-S2的双酶切与纯化:取10μg T-S2质粒,用BglII和NotI限制酶过夜酶切,胶回收一条包含T载体和S2片段约4000bp的DNA片段,即T-S2的双酶切后的目的产物,命名为ET-S2,-20℃保存备用;
所述A5步骤具体执行以下操作:
E-S1和ET-S2各取50ng,然后加入T4 DNA Ligase 1μl,10×T4 DNA Ligase Buffer 1μl,补充ddH2O至10μl,16℃过夜连接,热激法转化DH5α感受态细胞,涂布至含有氨苄霉素的固体LB平板上,12-16h后挑取单克隆菌落过夜摇菌,提取质粒后用XbaI和NotI限制酶酶切质粒,电泳检测,将酶切鉴定正确的质粒送测序公司测序,鉴定正确后即得含有srebp1基因CDS区全长的T克隆载体T-srebp1。
2.根据权利要求1所述的方法,其特征在于,所述A3.1步骤和A3.2步骤中,连接体系为19-T Simple Vector 1μl,Solution I 5μl,ddH2O 2μl。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910104768.6A CN110157711B (zh) | 2019-02-01 | 2019-02-01 | 一种人的srebp1基因编码区全长分段克隆的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910104768.6A CN110157711B (zh) | 2019-02-01 | 2019-02-01 | 一种人的srebp1基因编码区全长分段克隆的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110157711A CN110157711A (zh) | 2019-08-23 |
CN110157711B true CN110157711B (zh) | 2023-10-24 |
Family
ID=67645351
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910104768.6A Active CN110157711B (zh) | 2019-02-01 | 2019-02-01 | 一种人的srebp1基因编码区全长分段克隆的方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110157711B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200918509A (en) * | 2007-08-30 | 2009-05-01 | Pfizer Prod Inc | Pharmaceutical compounds and derivatives |
EP2292742A1 (en) * | 2009-08-31 | 2011-03-09 | Rheinische Friedrich-Wilhelms-Universität Bonn | New nucleic acid molecules and polypeptides involved in lipid metabolism |
CN104126006A (zh) * | 2011-11-28 | 2014-10-29 | 索拉兹米公司 | 包括原藻脂质通路基因的基因工程化的微生物株系 |
CN108367009A (zh) * | 2016-03-30 | 2018-08-03 | 雀巢产品技术援助有限公司 | 包含维生素的组合物及其用途 |
-
2019
- 2019-02-01 CN CN201910104768.6A patent/CN110157711B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200918509A (en) * | 2007-08-30 | 2009-05-01 | Pfizer Prod Inc | Pharmaceutical compounds and derivatives |
EP2292742A1 (en) * | 2009-08-31 | 2011-03-09 | Rheinische Friedrich-Wilhelms-Universität Bonn | New nucleic acid molecules and polypeptides involved in lipid metabolism |
CN104126006A (zh) * | 2011-11-28 | 2014-10-29 | 索拉兹米公司 | 包括原藻脂质通路基因的基因工程化的微生物株系 |
CN108367009A (zh) * | 2016-03-30 | 2018-08-03 | 雀巢产品技术援助有限公司 | 包含维生素的组合物及其用途 |
Non-Patent Citations (1)
Title |
---|
奶牛 SREBP1 蛋白在乳腺上皮细胞的表达定位及对 SCD1 基因启动子的转录调控;韩立强等;《中国农业科学》;20161231;第49卷(第24期);第4797-4805页 * |
Also Published As
Publication number | Publication date |
---|---|
CN110157711A (zh) | 2019-08-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Baumann et al. | Transcription: new insights from studies on Archaea | |
WO2009058285A3 (en) | PORCINE DC-SIGN, ICAM-3 AND LSECtin AND USES THEREOF | |
CN113265408B (zh) | 一种三七DOF转录因子基因PnDof1及其应用 | |
CN114829600A (zh) | 植物mad7核酸酶及其扩大的pam识别能力 | |
Mishra et al. | Constitutive over-expression of rice ClpD1 protein enhances tolerance to salt and desiccation stresses in transgenic Arabidopsis plants | |
CN110157711B (zh) | 一种人的srebp1基因编码区全长分段克隆的方法 | |
Ambartsumian et al. | Characterization of two splice variants of metastasis-associated human mts1 gene | |
JP2018536400A (ja) | ドリメノールシンターゼiii | |
Azevedo et al. | Sub-plastidial localization of two different phage-type RNA polymerases in spinach chloroplasts | |
Gupta et al. | Two novel arginine/serine (SR) proteins in maize are differentially spliced and utilize non-canonical splice sites | |
Obermeier et al. | Gene expression profiling via LongSAGE in a non-model plant species: a case study in seeds of Brassica napus | |
CN101490079A (zh) | 植物生长和耐逆性相关同功酶及其编码基因与应用 | |
CN108218969A (zh) | 甘薯花青素转运相关蛋白IbGSTF4及其编码基因与应用 | |
CN112359045A (zh) | 一种类胡萝卜素代谢途径相关基因及应用 | |
CN112877332A (zh) | 一种由双荧光素酶报告基因检测鸡ripk2启动子活性的方法 | |
Bolle et al. | Mono-and dicotyledonous plant-specific RNA editing sites are correctly edited in both in organello systems | |
CN105524928A (zh) | 桃PpeAMT1;1基因、转运蛋白、表达载体及其构建方法 | |
CN111500592A (zh) | GAPC1基因mRNA在葫芦科砧穗间运输的鉴定方法 | |
CN1285872A (zh) | 与植物疾病抗性相关的基因 | |
CN117821462B (zh) | 基因编辑修复阿尔兹海默症相关psen1位点突变 | |
CN110627884B (zh) | 一个双孢蘑菇乙烯受体蛋白Ab143539 | |
EP1034274A2 (en) | Plant homologs of yeast pad1, yeast crm1, and human jab1: regulators of ap-1 type transcription factor activity | |
CN114106124B (zh) | 一种能够提高蒜氨酸含量的大蒜AsNAC1转录因子基因及其应用 | |
CN113005106B (zh) | 玉米耐低温基因ZmCIPK10.1在提高植物抗寒性中的应用 | |
KR100974302B1 (ko) | 페투인이 발현된 감자 식물체 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |